Publications

Marullo R, Rutherford SC, Revuelta MV, Zamponi N, Culjkovic-Kraljacic B, Kotlov N, Di Siervi N, Lara-Garcia J, Allan JN, Ruan J et al..  2024.  XPO1 Enables Adaptive Regulation of mRNA Export Required for Genotoxic Stress Tolerance in Cancer Cells.. Cancer Res. 84(1):101-117.

Ruan J, Moskowitz AJ, Mehta-Shah N, Sokol L, Chen Z, Kotlov N, Nos G, Sorokina M, Maksimov V, Sboner A et al..  2023.  Multicenter Phase 2 Study of Oral azacitidine (CC-486) plus CHOP as initial treatment for peripheral T-cell lymphoma.. Blood.

Li M, Teater MR, Hong JYoung, Park NR, Duy C, Shen H, Wang L, Chen Z, Cerchietti L, Davidson SM et al..  2022.  Translational Activation of ATF4 through Mitochondrial Anaplerotic Metabolic Pathways Is Required for DLBCL Growth and Survival.. Blood Cancer Discov. 3(1):50-65.

Li M, Chiang Y-L, Lyssiotis CA, Teater MR, Hong JYoung, Shen H, Wang L, Hu J, Jing H, Chen Z et al..  2019.  Non-oncogene Addiction to SIRT3 Plays a Critical Role in Lymphomagenesis.. Cancer Cell. 35(6):916-931.e9.

Rutherford SC, Stewart EN, Chen Z, Chadburn A, Wehrli NE, van Besien K, Martin P, Furman RR, Leonard JP, Cerchietti L.  2018.  The eIF4E inhibitor ribavirin as a potential antilymphoma therapeutic: early clinical data^.. Leuk Lymphoma. 59(1):256-258.

Rutherford SC, Stewart EN, Chen Z, Chadburn A, Wehrli NE, van Besien K, Martin P, Furman RR, Leonard JP, Cerchietti L.  2017.  The eIF4E inhibitor ribavirin as a potential antilymphoma therapeutic: early clinical data.. Leuk Lymphoma. :1-3.